Sökning: WFRF:(Sandström Lars) > (2010-2014) > Imaging of Insulinl...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04163naa a2200505 4500 | |
001 | oai:DiVA.org:kth-75532 | |
003 | SwePub | |
008 | 120206s2012 | |||||||||||000 ||eng| | |
009 | oai:DiVA.org:uu-164418 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-755322 URI |
024 | 7 | a https://doi.org/10.2967/jnumed.111.0908292 DOI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-1644182 URI |
040 | a (SwePub)kthd (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Tolmachev, Vladimiru Uppsala universitet,Enheten för biomedicinsk strålningsvetenskap,Vladimir Tolmachev4 aut0 (Swepub:uu)vladtolm |
245 | 1 0 | a Imaging of Insulinlike Growth Factor Type 1 Receptor in Prostate Cancer Xenografts Using the Affibody Molecule (111)In-DOTA-Z(IGF1R:4551) |
264 | c 2011-12-15 | |
264 | 1 | b Society of Nuclear Medicine,c 2012 |
338 | a print2 rdacarrier | |
500 | a QC 20120206 | |
520 | a One of the pathways leading to androgen independence in prostate cancer involves upregulation of insulinlike growth factor type 1 receptor (IGF-1R). Radionuclide imaging of IGF-1R in tumors might be used for selection of patients who would most likely benefit from IGF-1R-targeted therapy. The goal of this study was to evaluate the feasibility of in vivo radionuclide imaging of IGF-1R expression in prostate cancer xenografts using a small nonimmunoglobulin-derived binding protein called an Affibody molecule. Methods: The IGF-1R-binding Z(IGF1R:4551) Affibody molecule was site-specifically conjugated with a maleimido derivative of DOTA and labeled with (111)In. The binding of radiolabeled Z(IGF1R:4551) to IGF-1R-expressing cells was evaluated in vitro and in vivo. Results: DOTA-Z(IGF1R:4551) can be stably labeled with (111)In with preserved specific binding to IGF-1R-expressing cells in vitro. In mice, (111)In-DOTAZ(IGF1R):(4551) accumulated in IGF-1R-expressing organs (pancreas, stomach, lung, and salivary gland). Receptor saturation experiments demonstrated that targeting of DU-145 prostate cancer xenografts in NMRI nu/nu mice was IGF-1R-specific. The tumor uptake was 1.1 +/- 0.3 percentage injected dose per gram, and the tumor-to-blood ratio was 3.2 +/- 0.2 at 8 h after injection. Conclusion: This study demonstrates the feasibility of in vivo targeting of IGF-1R-expressing prostate cancer xenografts using an Affibody molecule. Further development of radiolabeled Affibody molecules might provide a useful clinical tool for stratification of patients with prostate cancer for IGF-1R-targeting therapy. | |
650 | 7 | a NATURVETENSKAPx Biologix Biokemi och molekylärbiologi0 (SwePub)106022 hsv//swe |
650 | 7 | a NATURAL SCIENCESx Biological Sciencesx Biochemistry and Molecular Biology0 (SwePub)106022 hsv//eng |
653 | a Affibody molecule | |
653 | a (111)In | |
653 | a molecular imaging | |
653 | a IGF-1R | |
653 | a DU145 xenograft | |
700 | 1 | a Malmberg, Jennieu Uppsala universitet,Plattformen för preklinisk PET,Anna Orlova4 aut0 (Swepub:uu)jenma183 |
700 | 1 | a Hofström, Camillau KTH,Molekylär Bioteknologi4 aut0 (Swepub:kth)u12237py |
700 | 1 | a Abrahmsén, Lars4 aut |
700 | 1 | a Bergman, Thomas4 aut |
700 | 1 | a Sjöberg, Anna4 aut |
700 | 1 | a Sandström, Mattiasu Uppsala universitet,Enheten för onkologi,Enheten för radiologi4 aut0 (Swepub:uu)masan637 |
700 | 1 | a Gräslund, Torbjörnu KTH,Molekylär Bioteknologi4 aut0 (Swepub:kth)u1dl39rj |
700 | 1 | a Orlova, Annau Uppsala universitet,Plattformen för preklinisk PET,Anna Orlova4 aut0 (Swepub:uu)annaorlo |
710 | 2 | a Uppsala universitetb Enheten för biomedicinsk strålningsvetenskap4 org |
773 | 0 | t Journal of Nuclear Medicined : Society of Nuclear Medicineg 53:1, s. 90-97q 53:1<90-97x 0161-5505x 1535-5667x 2159-662X |
856 | 4 | u http://jnm.snmjournals.org/content/53/1/90.full.pdf |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-75532 |
856 | 4 8 | u https://doi.org/10.2967/jnumed.111.090829 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-164418 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy